CD4 and B-cell non-Hodgkin lymphoma: Thus, to validate the relevance of this interplay, we used CRISPR-Cas9, and two distinct guide RNAs, to KO CD74 expression in the A20 and 2PK-3 B cell lymphoma models and found that similarly to loss of IRF8, KO of CD74 resulted in significantly diminished CD4 activation (Fig. 5F and fig.